MBX Biosciences Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, MBX Biosciences stock has a consensus rating of "Buy" and an average price target of $69.09. The average 1-year stock price forecast is 122.94% higher than the current stock price, while the lowest is $20 (-35.46%) and the highest is $91 (+193.64%).

Price Target: $69.09 (+122.94%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$20	$69.09	$70	$91
Change	-35.46%	+122.94%	+125.88%	+193.64%

Analyst Ratings

The average analyst rating for MBX Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	8	8	9	9	9	9
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	1
Total	11	11	12	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Uy Ear Mizuho Securities	Mizuho Securities	Buy Reiterates $57	Buy	Reiterates	$57	+83.93%	Jun 4, 2026
Patrick Dolezal LifeSci Capital	LifeSci Capital	Buy Maintains $75 → $91	Buy	Maintains	$75 → $91	+193.64%	May 16, 2026
Unknown Analyst Oppenheimer No rating	Oppenheimer	Buy Reiterates $80	Buy	Reiterates	$80	+158.15%	May 12, 2026
Annabel Samimy Stifel Nicolaus	Stifel Nicolaus	Buy Reiterates $50 → $56	Buy	Reiterates	$50 → $56	+80.70%	May 12, 2026
Jonathan Wolleben Citizens JMP	Citizens JMP	Buy Maintains $76 → $86	Buy	Maintains	$76 → $86	+177.51%	May 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-2.75

from -2.38

EPS Next Year

-3.94

from -2.75

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-
Operating Income	-25.16M	-35.31M	-68.19M	-98.06M	-145.58M
Net Income	-26.14M	-32.56M	-61.92M	-86.97M	-133.51M
EPS	-	-	-	-2.38	-2.75
Free Cash Flow	-	-20.56M	-33.27M	-52.44M	-126.00M
No. Analysts	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.75
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-